ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines

Circulation

Volumn 114, Issue 10, 2006, Pages 1088-1132

  Zipes, Douglas P ^a   Camm, A John ^a   Borggrefe, Martin ^a   Buxton, Alfred E ^a   Chaitman, Bernard ^a   Fromer, Martin ^a   Gregoratos, Gabriel ^a   Klein, George ^a   Moss, Arthur J ^a   Myerburg, Robert J ^a   Priori, Silvia G ^a   Quinones, Miguel A ^a   Roden, Dan M ^a   Silka, Michael J ^a   Tracy, Cynthia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AJMALINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIGITALIS; DILTIAZEM; DIURETIC AGENT; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENALINE; ITRACONAZOLE; KETOCONAZOLE; LIDOCAINE; MAGNESIUM; MAGNESIUM SULFATE; MEXILETINE; PHENYTOIN; POTASSIUM; PROCAINAMIDE; QUINIDINE; RADIOISOTOPE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TRICYCLIC ANTIDEPRESSANT AGENT; TROPONIN; UNINDEXED DRUG; VERAPAMIL;

ACUTE CORONARY SYNDROME; ALCOHOL CONSUMPTION; ANGIOCARDIOGRAPHY; ANOREXIA; ATHLETE; BRADYCARDIA; BRUGADA SYNDROME; CARDIOTOXICITY; CARDIOVASCULAR RISK; CATHETER ABLATION; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; DEMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG OVERDOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; ELECTROPHYSIOLOGY; ENDOCARDITIS; ENDOCRINE DISEASE; EVIDENCE BASED PRACTICE; EXERCISE; GENETIC ANALYSIS; HEART ARREST; HEART BLOCK; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART PACING; HEART RIGHT VENTRICLE DYSPLASIA; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERKALEMIA; HYPERTROPHIC CARDIOMYOPATHY; IDIOPATHIC DISEASE; INCIDENCE; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIFESTYLE; LONG QT SYNDROME; MEDICAL SOCIETY; META ANALYSIS; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; MYOCARDITIS; NEUROMUSCULAR DISEASE; OBESITY; PERICARDIAL DISEASE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVASCULARIZATION; REVIEW; RHEUMATIC DISEASE; SYNCOPE; SYSTEMATIC REVIEW; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 33748599252     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.178104     Document Type: Review

References (314)

1. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002;106:2145-61.
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:E1-211.
3. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22:1374-450.
4. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003;24:13-5.
5. Swedberg K, Cleland J, Dargie H, et al. Executive summary of the guidelines for the diagnosis and treatment of chronic heart failure: the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
6. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82.
7. Buxton AE. A report of the American College of Cardiology Task Force on Clinical Data Standards (Electrophysiolology Writing Committee). Manuscript in preparation.
8. Poole JE, Bardy GH, Sudden Cardiac Death. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell to Bedside. 3rd edition. Philadelphia, PA: W.B. Saunders Company, 2000:615-640.
9. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
10. Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation 1989;79:756-65.
11. Escobedo LG, Zack MM. Comparison of sudden and nonsudden coronary deaths in the United States. Circulation 1996;93:2033-6.
12. Zheng ZJ, Croft JB, Giles WH, et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104:2158-63.
13. Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 2002;288:3008-13.
14. American Heart Association; Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX: American Heart Association; 2004.
15. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993;119:1187-97.
16. Kuller L, Lilienfeld A, Fisher R. An epidemiological study of sudden and unexpected deaths in adults. Medicine (Baltimore) 1967;46:341-61.
17. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997;30:1500-5.
18. Gillum RF. Geographic variation in sudden coronary death. Am Heart J 1990;119:380-9.
19. Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovasc Electrophysiol 2001;12:369-81.
20. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.
21. Braunwald E. Shattuck lecture- cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
22. Myerburg RJ, Mitrani R, Interian A Jr., Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 1998;97:1514-21.
23. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002;40:1531-40.
24. Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. N Engl J Med 2000;343:826-33.
25. Frolkis JP, Pothier CE, Blackstone EH, et al. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 2003;348:781-90.
26. Huikuri HV, Makikallio TH, Raatikainen MJ, et al. Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation 2003;108:110-5.
27. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the Clinical Application of Echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997;95:1686-744.
28. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 2003;42:954-70.
29. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
30. Ross DL, Farre J, Bar FW, et al. Comprehensive clinical electrophysiologic studies in the investigation of documented or suspected tachycardias. Time, staff, problems and costs. Circulation 1980;61:1010-6.
31. Freedman RA, Swerdlow CD, Soderholm-Difatte V, et al. Prognostic significance of arrhythmia inducibility or noninducibility at initial electrophysiologic study in survivors of cardiac arrest. Am J Cardiol 1988;61:578-82.
32. Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 1988;318:19-24.
33. Mittal S, Iwai S, Stein KM, et al. Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era. J Am Coll Cardiol 1999;34:1082-9.
34. Gurevitz O, Viskin S, Glikson M, et al. Long-term prognosis of inducible ventricular flutter: not an innocent finding. Am Heart J 2004;147:649-54.
35. Viskin S, Justo D, Halkin A, et al. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003;45:415-27.
36. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-47.
37. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 1991;84:1831-51.
38. Reiter MJ, Reiffel JA. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 1998;82:9I-19I.
39. Ellison KE, Hafley GE, Hickey K, et al. Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). Circulation 2002;106:2694-9.
40. Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol 1999;84:90R-3R.
41. Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001;142:520-9.
42. Farre J, Romero J, Rubio JM, et al. Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials. Am J Cardiol 1999;83:55D-63D.
43. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501-8.
44. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-24.
45. Janse MJ, Malik M, Camm AJ, et al. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). Eur Heart J 1998;19:85-95.
46. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999;99:2268-75.
47. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999;340:1855-62.
48. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
49. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997;337:1569-75.
50. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
51. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.
52. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
53. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003;41:1573-82.
54. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003;138:445-52.
55. Marenco JP, Wang PJ, Link MS, et al. Improving survival from sudden cardiac arrest: the role of the automated external defibrillator. JAMA 2001;285:1193-200.
56. Priori SG, Bossaert LL, Chamberlain DA, et al. ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. Eur Heart J 2004;25:437-45.
57. Koster RW. Automatic external defibrillator: key link in the chain of survival. J Cardiovasc Electrophysiol 2002;13:S92-S95.
58. Valenzuela TD, Roe DJ, Nichol G, et al. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med 2000;343:1206-9.
59. Caffrey SL, Willoughby PJ, Pepe PE, et al. Public use of automated external defibrillators. N Engl J Med 2002;347:1242-7.
60. Silva RM, Mont L, Nava S, et al. Radiofrequency catheter ablation for arrhythmic storm in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2004;27:971-5.
61. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003;108:3092-6.
62. Pappone C, Santinelli V, Manguso F, et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 2003;349:1803-11.
63. Haissaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation 2002;106:962-7.
64. Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 2005;45:1259-65.
65. Scheinman MM. NASPE survey on catheter ablation. Pacing Clin Electrophysiol 1995;18:1474-8.
66. Twidale N, Hazlitt HA, Berbari EJ, et al. Late potentials are unaffected by radiofrequency catheter ablation in patients with ventricular tachycardia. Pacing Clin Electrophysiol 1994;17:157-65.
67. SippensGroenewegen A, Spekhorst H, van Hemel NM, et al. Localization of the site of origin of postinfarction ventricular tachycardia by endocardial pace mapping. Body surface mapping compared with the 12-lead electrocardiogram. Circulation 1993;88:2290-306.
68. Morady F, Harvey M, Kalbfleisch SJ, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. Circulation 1993;87:363-72.
69. Stevenson WG, Khan H, Sager P, et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation 1993;88:1647-70.
70. Cohen TJ, Chien WW, Lurie KG, et al. Radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia: results and long-term follow-up. J Am Coll Cardiol 1991;18:1767-73.
71. Tchou P, Jazayeri M, Denker S, et al. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 1988;78:246-57.
72. Nakagawa H, Beckman KJ, McClelland JH, et al. Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation 1993;88:2607-17.
73. Page RL, Shenasa H, Evans JJ, et al. Radiofrequency catheter ablation of idiopathic recurrent ventricular tachycardia with right bundle branch block, left axis morphology. Pacing Clin Electrophysiol 1993;16:327-36.
74. Klein LS, Shih HT, Hackett FK, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. Circulation 1992;85:1666-74.
75. Calkins H, Kalbfleisch SJ, el-Atassi R, et al. Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. Am J Cardiol 1993;71:827-33.
76. Kim YH, Sosa-Suarez G, Trouton TG, et al. Treatment of ventricular tachycardia by transcatheter radiofrequency ablation in patients with ischemic heart disease. Circulation 1994;89:1094-102.
77. Coggins DL, Lee RJ, Sweeney J, et al. Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. J Am Coll Cardiol 1994;23:1333-41.
78. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004;109:1826-33.
79. Carnendran L, Steinberg JS. Does an open infarct-related artery after myocardial infarction improve electrical stability? Prog Cardiovasc Dis 2000;42:439-54.
80. Hillis LD, Cigarroa JE, Lange RA. Late revascularization reduces mortality in survivors of myocardial infarction. Cardiol Rev 1999;7:144-8.
81. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2005;112:IV1-203.
82. Nolan JP, Deakin CD, Soar J, et al. European Resuscitation Council Guidelines for Resuscitation 2005 Section 4. Adult advanced life support. Resuscitation 2005;67 Suppl 1:S39-86.
83. Antman EM, Berlin JA. Declining incidence of ventricular fibrillation in myocardial infarction. Implications for the prophylactic use of lidocaine. Circulation 1992;86:764-73.
84. Behar S, Goldbourt U, Reicher-Reiss H, et al. Prognosis of acute myocardial infarction complicated by primary ventricular fibrillation. Principal Investigators of the SPRINT Study. Am J Cardiol 1990;66:1208-11.
85. MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA 1988;260:1910-6.
86. Higham PD, Adams PC, Murray A, et al. Plasma potassium, serum magnesium and ventricular fibrillation: a prospective study. Q J Med 1993;86:609-17.
87. Gorgels AP, van den Dool A, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996;78:43-6.
88. Callans DJ, Marchlinski FE. Dissociation of termination and prevention of inducibility of sustained ventricular tachycardia with infusion of procainamide: evidence for distinct mechanisms. J Am Coll Cardiol 1992;19:111-7.
89. Sharma AD, Purves P, Yee R, et al. Hemodynamic effects of intravenous procainamide during ventricular tachycardia. Am Heart J 1990;119:1034-41.
90. Nasir N Jr., Taylor A, Doyle TK, et al. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction. Am J Cardiol 1994;74:1183-6.
91. Lie KI, Wellens HJ, van Capelle FJ, et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. N Engl J Med 1974;291:1324-6.
92. Buxton AE, Marchlinski FE, Doherty JU, et al. Repetitive, monomorphic ventricular tachycardia: clinical and electrophysiologic characteristics in patients with and patients without organic heart disease. Am J Cardiol 1984;54:997-1002.
93. Rahilly GT, Prystowsky EN, Zipes DP, et al. Clinical and electrophysiologic findings in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram. Am J Cardiol 1982;50:459-68.
94. Lerman BB, Stein K, Engelstein ED, et al. Mechanism of repetitive monomorphic ventricular tachycardia. Circulation 1995;92:421-9.
95. Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol 2002;39:500-8.
96. Sadanaga T, Saeki K, Yoshimoto T, et al. Repetitive monomorphic ventricular tachycardia of left coronary cusp origin. Pacing Clin Electrophysiol 1999;22:1553-6.
97. Grimm W, Menz V, Hoffmann J, et al. Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol 2001;24:166-71.
98. Buxton AE, Waxman HL, Marchlinski FE, et al. Right ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation 1983;68:917-27.
99. Fung JW, Chan HC, Chan JY, et al. Ablation of nonsustained or hemodynamically unstable ventricular arrhythmia originating from the right ventricular outflow tract guided by noncontact mapping. Pacing Clin Electrophysiol 2003;26:1699-705.
100. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000;102:742-7.
101. Kowey PR, Marinchak RA, Rials SJ, et al. Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation. Am J Cardiol 1999;84:46R-51R.
102. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. Circulation 2000;102:I112-8.
103. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 7: algorithm approach to ACLS emergencies: section 7A: principles and practice of ACLS. Circulation 2000;102:I136-9.
104. Dorian P, Cass D. An overview of the management of electrical storm. Can J Cardiol 1997;13 Suppl A:13A-7A.
105. Bonow RO, Carabello B, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 2006;48:e1-148.
106. State-specific mortality from sudden cardiac death - United States, 1999. MMWR Morb Mortal Wkly Rep 2002;51:123-6.
107. Silka MJ, Hardy BG, Menashe VD, et al. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 1998;32:245-51.
108. Oechslin EN, Harrison DA, Connelly MS, et al. Mode of death in adults with congenital heart disease. Am J Cardiol 2000;86:1111-6.
109. Graham TP Jr., Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol 2000;36:255-61.
110. Alexander ME, Walsh EP, Saul JP, et al. Value of programmed ventricular stimulation in patients with congenital heart disease. J Cardiovasc Electrophysiol 1999;10:1033-44.
111. Fish FA, Gillette PC, Benson DW Jr. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. J Am Coll Cardiol 1991;18:356-65.
112. Jonas M, Hod H. Is immunosuppressive treatment an option for myocarditis? Isr J Med Sci 1997;33:762-6.
113. Tai YT, Lau CP, Fong PC, et al. Incessant automatic ventricular tachycardia complicating acute coxsackie B myocarditis. Cardiology 1992;80:339-44.
114. Tubman TR, Craig B, Mulholland HC. Ventricular tachycardia associated with Coxsackie B4 virus infection. Acta Paediatr Scand 1990;79:572-5.
115. Gowrishankar K, Rajajee S. Varied manifestations of viral myocarditis. Indian J Pediatr 1994;61:75-80.
116. Mary AS, Hamilton M. Ventricular tachycardia in a patient with toxoplasmosis. Br Heart J 1973;35:349-52.
117. Etherington J, Salmon J, Ratcliffe G. Atrio-ventricular dissociation in meningococcal meningitis. J R Army Med Corps 1995;141:169-71.
118. Dhar KL, Adlakha A, Phillip PJ. Recurrent seizures and syncope, ventricular arrhythmias with reversible prolonged Q-Tc interval in typhoid myocarditis. J Indian Med Assoc 1987;85:336-7.
119. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 1999;99:1091-100.
120. Winkel E, Parrillo J. Myocarditis. Curr Treat Options Cardiovasc Med 2002;4:455-66.
121. Mayer W, Kleber FX, Wilske B, et al. Persistent atrioventricular block in Lyme borreliosis. Klin Wochenschr 1990;68:431-5.
122. Nagi KS, Thakur RK. Lyme carditis: indications for cardiac pacing. Can J Cardiol 1995;11:335-8.
123. Rassi A Jr., Rassi A, Little WC. Chagas' heart disease. Clin Cardiol 2000;23:883-9.
124. Muratore C, Rabinovich R, Iglesias R, et al. Implantable cardioverter defibrillators in patients with Chagas' disease: are they different from patients with coronary disease? Pacing Clin Electrophysiol 1997;20:194-7.
125. Malik JA, Hassan C, Khan GQ. Transient complete heart block complicating acute rheumatic fever. Indian Heart J 2002;54:91-2.
126. Liberman L, Hordof AJ, Alfayyadh M, et al. Torsade de pointes in a child with acute rheumatic fever. J Pediatr 2001;138:280-2.
127. Freed MS, Sacks P, Ellman MH. Ventricular tachycardia in acute rheumatic fever. Arch Intern Med 1985;145:1904-5.
128. Wallace SM, Walton BI, Kharbanda RK, et al. Mortality from infective endocarditis: clinical predictors of outcome. Heart 2002;88:53-60.
129. Drenick EJ, Fisler JS. Sudden cardiac arrest in morbidly obese surgical patients unexplained after autopsy. Am J Surg 1988;155:720-6.
130. Sjostrom LV. Mortality of severely obese subjects. Am J Clin Nutr 1992;55:516S-23S.
131. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 2003;41:1429-37.
132. Neumarker KJ. Mortality and sudden death in anorexia nervosa. Int J Eat Disord 1997;21:205-12.
133. Wyse DG, Friedman PL, Brodsky MA, et al. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol 2001;38:1718-24.
134. Kliegel A, Eisenburger P, Sterz F, et al. Survivors of ventricular tachyarrhythmias due to a transient or reversible disorder have a high recurrence rate of lethal cardiac events. Resuscitation 2002;54:237-43.
135. Brugada J, Aguinaga L, Mont L, et al. Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol 2001;37:529-33.
136. Kelly P, Ruskin JN, Vlahakes GJ, et al. Surgical coronary revascularization in survivors of prehospital cardiac arrest: its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol 1990;15:267-73.
137. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994;331:1564-75.
138. Di LA, Secoli G, Perkan A, et al. Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group. Br Heart J 1994;72:S46-S51.
139. Sugrue DD, Rodeheffer RJ, Codd MB, et al. The clinical course of idiopathic dilated cardiomyopathy. A population-based study. Ann Intern Med 1992;117:117-23.
140. Komajda M, Jais JP, Reeves F, et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 1990;11:824-31.
141. Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989;80:1675-80.
142. Kelly P, Coats A. Variation in mode of sudden cardiac death in patients with dilated cardiomyopathy. Eur Heart J 1997;18:879-80.
143. Tamburro P, Wilber D. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 1992;124:1035-45.
144. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493-8.
145. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333:77-82.
146. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.
147. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-54.
148. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071-8.
149. Kadish A, Quigg R, Schaechter A, et al. Defibrillators in nonischemic cardiomyopathy treatment evaluation. Pacing Clin Electrophysiol 2000;23:338-43.
150. Grimm W, Alter P, Maisch B. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT. Herz 2004;29:348-52.
151. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-8.
152. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8.
153. Spirito P, Bellone P. Natural history of hypertrophic cardiomyopathy. Br Heart J 1994;72:S10-S12.
154. Louie EK, Edwards LC III. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis 1994;36:275-308.
155. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995;92:1680-92.
156. DeRose JJ Jr., Banas JS Jr., Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis 1994;36:475-84.
157. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 1987;316:844-52.
158. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987;316:780-9.
159. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982;65:1388-94.
160. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987-91.
161. Mittal SR. Sudden cardiac death in hypertrophic cardiomyopathy: risk evaluation. Int J Cardiol 1995;52:1-4.
162. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
163. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-713.
164. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
165. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990;15:1279-85.
166. McKenna WJ, Harris L, Rowland E, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 1984;54:802-10.
167. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
168. Maron BJ, Estes NA III, Maron MS, et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003;107:2872-5.
169. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol 1997;30:1512-20.
170. Schionning JD, Frederiksen P, Kristensen IB. Arrhythmogenic right ventricular dysplasia as a cause of sudden death. Am J Forensic Med Pathol 1997;18:345-8.
171. Munclinger MJ, Patel JJ, Mitha AS. Follow-up of patients with arrhythmogenic right ventricular cardiomyopathy dysplasia. S Afr Med J 2000;90:61-8.
172. Link MS, Wang PJ, Haugh CJ, et al. Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators. J Interv Card Electrophysiol 1997;1:41-8.
173. Hauer RN, Aliot E, Block M, et al. Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology. Eur Heart J 2001;22:1074-81.
174. Myerburg RJ, Castellanos A. Clinical trials of implantable defibrillators. N Engl J Med 1997;337:1621-3.
175. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter- defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;108:3084-91.
176. DeSilva RA. Central nervous system risk factors for sudden cardiac death. Ann N Y Acad Sci 1982;382:143-61.
177. Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol 1997;12:329-43.
178. Pelargonio G, Dello RA, Sanna T, et al. Myotonic dystrophy and the heart. Heart 2002;88:665-70.
179. Munoz J, Sanjuan R, Morell JS, et al. Ventricular tachycardia in Duchenne's muscular dystrophy. Int J Cardiol 1996;54:259-62.
180. Samuels MA. Neurally induced cardiac damage. Definition of the problem. Neurol Clin 1993;11:273-92.
181. Merino JL, Peinado R. Arrhythmias associated with neuromuscular disorders. Card Electrophysiol Rev 2002;6:132-5.
182. Becane HM, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 2000;23:1661-6.
183. Colleran JA, Hawley RJ, Pinnow EE, et al. Value of the electrocardiogram in determining cardiac events and mortality in myotonic dystrophy. Am J Cardiol 1997;80:1494-7.
184. Corrado G, Lissoni A, Beretta S, et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol 2002;89:838-41.
185. Ducceschi V, Nigro G, Sarubbi B, et al. Autonomic nervous system imbalance and left ventricular systolic dysfunction as potential candidates for arrhythmogenesis in Becker muscular dystrophy. Int J Cardiol 1997;59:275-9.
186. Perloff JK, Stevenson WG, Roberts NK, et al. Cardiac involvement in myotonic muscular dystrophy (Steinert's disease): a prospective study of 25 patients. Am J Cardiol 1984;54:1074-81.
187. Hiromasa S, Ikeda T, Kubota K, et al. Myotonic dystrophy: ambulatory electrocardiogram, electrophysiologic study, and echocardiographic evaluation. Am Heart J 1987;113:1482-8.
188. Stevenson WG, Perloff JK, Weiss JN, et al. Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 1990;15:292-9.
189. James TN, Fisch C. Observations on the cardiovascular involvement in Friedreich's ataxia. Am Heart J 1963;66:164-75.
190. Roberts NK, Perloff JK, Kark RA. Cardiac conduction in the Kearns-Sayre syndrome (a neuromuscular disorder associated with progressive external ophthalmoplegia and pigmentary retinopathy). Report of 2 cases and review of 17 published cases. Am J Cardiol 1979;44:1396-400.
191. Charles R, Holt S, Kay JM, et al. Myocardial ultrastructure and the development of atrioventricular block in Kearns-Sayre syndrome. Circulation 1981;63:214-9.
192. James TN. Observations on the cardiovascular involvement, including the cardiac conduction system, in progressive muscular dystrophy. Am Heart J 1962;63:48-56.
193. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105:1453-8.
194. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVERT. J Am Coll Cardiol 2003;41:1707-12.
195. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-80.
196. Leon AR, Abraham WT, Curtis AB, et al. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. J Am Coll Cardiol 2005;46:2348-56.
197. Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute for Genectic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). Available at: http://www.ncbi.nlm.nih.gov/omim. Accessed June 6, 2003.
198. Decision No. 1295/1999 EC of the European Parliament and of the Council of 29 April 1999. Official Journal of the European Communities; L155:1-5. Accessed June 22, 2003.
199. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84:1136-44.
200. Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. Circulation 2001;104:557-62.
201. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74.
202. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004;119:19-31.
203. Marks ML, Whisler SL, Clericuzio C, et al. A new form of long QT syndrome associated with syndactyly. J Am Coll Cardiol 1995;25:59-64.
204. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000;101:616-23.
205. Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. J Am Coll Cardiol 2005;45:1318-21.
206. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 2005;294:2975-80.
207. Kannankeril PJ, Roden DM, Fish FA. Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen's syndrome. J Cardiovasc Electrophysiol 2004;15:119.
208. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391-6.
209. Alings M, Dekker L, Sadee A, et al. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001;24:1420-2.
210. Mok NS, Chan NY, Chiu AC. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol 2004;27:821-3.
211. Maury P, Couderc P, Delay M, et al. Electrical storm in Brugada syndrome successfully treated using isoprenaline. Europace 2004;6:130-3.
212. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995;91:1512-9.
213. Deal BJ, Miller SM, Scagliotti D, et al. Ventricular tachycardia in a young population without overt heart disease. Circulation 1986;73:1111-8.
214. Proclemer A, Ciani R, Feruglio GA. Right ventricular tachycardia with left bundle branch block and inferior axis morphology: clinical and arrhythmological characteristics in 15 patients. Pacing Clin Electrophysiol 1989;12:977-89.
215. Mehta D, Odawara H, Ward DE, et al. Echocardiographic and histologic evaluation of the right ventricle in ventricular tachycardias of left bundle branch block morphology without overt cardiac abnormality. Am J Cardiol 1989;63:939-44.
216. Morady F, Kadish AH, DiCarlo L, et al. Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation 1990;82:2093-9.
217. O'Connor BK, Case CL, Sokoloski MC, et al. Radiofrequency catheter ablation of right ventricular outflow tachycardia in children and adolescents. J Am Coll Cardiol 1996;27:869-74.
218. Movsowitz C, Schwartzman D, Callans DJ, et al. Idiopathic right ventricular outflow tract tachycardia: narrowing the anatomic location for successful ablation. Am Heart J 1996;131:930-6.
219. Lerman BB, Belardinelli L, West GA, et al. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation 1986;74:270-80.
220. Lerman BB. Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation 1993;87:382-90.
221. Wilber DJ, Baerman J, Olshansky B, et al. Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation. Circulation 1993;87:126-34.
222. Lemery R, Brugada P, Bella PD, et al. Nonischemic ventricular tachycardia. Clinical course and long-term follow-up in patients without clinically overt heart disease. Circulation 1989;79:990-9.
223. Goy JJ, Tauxe F, Fromer M, Schlapfer J, Vogt P, Kappenberger L. Ten-year follow-up of 20 patients with idiopathic ventricular tachycardia. Pacing Clin Electrophysiol 1990;13:1142-7.
224. Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J 2002;144:e10.
225. Mont L, Seixas T, Brugada P, et al. Clinical and electrophysiologic characteristics of exercise-related idiopathic ventricular tachycardia. Am J Cardiol 1991;68:897-900.
226. Hayashi H, Fujiki A, Tani M, et al. Circadian variation of idiopathic ventricular tachycardia originating from right ventricular outflow tract. Am J Cardiol 1999;84:99-101.
227. Gill JS, Blaszyk K, Ward DE, et al. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J 1993;126:1126-33.
228. Davidson S, Surawicz B. Ectopic beats and atrioventricular conduction disturbances. In patients with hypopotassemia. Arch Intern Med 1967;120:280-5.
229. Hollifield JW. Thiazide treatment of hypertension. Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy. Am J Med 1986;80:8-12.
230. Hollifield JW. Thiazide treatment of systemic hypertension: effects on serum magnesium and ventricular ectopic activity. Am J Cardiol 1989;63:22G-5G.
231. Podrid PJ. Potassium and ventricular arrhythmias. Am J Cardiol 1990;65:33E-44E.
232. Dyckner T, Helmers C, Wester PO. Cardiac dysrhythmias in patients with acute myocardial infarction. Relation to serum potassium level and prior diuretic therapy. Acta Med Scand 1984;216:127-32.
233. Nordrehaug JE, von der Lippe G. Hypokalaemia and ventricular fibrillation in acute myocardial infarction. Br Heart J 1983;50:525-9.
234. Nordrehaug JE, Johannessen KA, von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. Circulation 1985;71:645-9.
235. Kafka H, Langevin L, Armstrong PW. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch Intern Med 1987;147:465-9.
236. Hulting J. In-hospital ventricular fibrillation and its relation to serum potassium. Acta Med Scand Suppl 1981;647:109-16.
237. Thompson RG, Cobb LA. Hypokalemia after resuscitation from out-of-hospital ventricular fibrillation. JAMA 1982;248:2860-3.
238. Glass JD, McQuillen EN, Hardin NJ. Iatrogenic cardiac herniation: post mortem case. J Trauma 1984;24:632-3.
239. Chadda KD, Lichstein E, Gupta P. Hypomagnesemia and refractory cardiac arrhythmia in a nondigitalized patient. Am J Cardiol 1973;31:98-100.
240. Tzivoni D, Keren A, Cohen AM, et al. Magnesium therapy for torsades de pointes. Am J Cardiol 1984;53:528-30.
241. Solomon RJ. Ventricular arrhythmias in patients with myocardial infarction and ischaemia. Relationship to serum potassium and magnesium. Drugs 1984;28 Suppl 1:66-76.
242. Sjogren A, Edvinsson L, Fallgren B. Magnesium deficiency in coronary artery disease and cardiac arrhythmias. J Intern Med 1989;226:213-22.
243. Rasmussen HS, McNair P, Norregard P, et al. Intravenous magnesium in acute myocardial infarction. Lancet 1986;1:234-6.
244. Abraham AS, Rosenmann D, Kramer M, et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med 1987;147:753-5.
245. Rasmussen HS, Suenson M, McNair P, et al. Magnesium infusion reduces the incidence of arrhythmias in acute myocardial infarction. A double-blind placebo-controlled study. Clin Cardiol 1987;10:351-6.
246. Smith LF, Heagerty AM, Bing RF, et al. Intravenous infusion of magnesium sulphate after acute myocardial infarction: effects on arrhythmias and mortality. Int J Cardiol 1986;12:175-83.
247. Hollifield JW. Magnesium depletion, diuretics, and arrhythmias. Am J Med 1987;82:30-7.
248. Rajs J, Rajs E, Lundman T. Unexpected death in patients suffering from eating disorders. A medico-legal study. Acta Psychiatr Scand 1986;74:587-96.
249. Iseri LT, Freed J, Bures AR. Magnesium deficiency and cardiac disorders. Am J Med 1975;58:837-46.
250. Zwerling HK. Does exogenous magnesium suppress myocardial irritability and tachyarrhythmias in the nondigitalized patient? Am Heart J 1987;113:1046-53.
251. Spies CD, Sander M, Stangl K, et al. Effects of alcohol on the heart. Curr Opin Crit Care 2001;7:337-43.
252. Albert CM, Manson JE, Cook NR, et al. Moderate alcohol consumption and the risk of sudden cardiac death among U.S. male physicians. Circulation 1999;100:944-50.
253. Dyer AR, Stamler J, Paul O, et al. Alcohol consumption, cardiovascular risk factors, and mortality in two Chicago epidemiologic studies. Circulation 1977;56:1067-74.
254. Wannamethee G, Shaper AG. Alcohol and sudden cardiac death. Br Heart J 1992;68:443-8.
255. Ettinger PO, Wu CF, De La Cruz C Jr., et al. Arrhythmias and the "Holiday Heart": alcohol-associated cardiac rhythm disorders. Am Heart J 1978;95:555-62.
256. Chenet L, McKee M, Leon D, et al. Alcohol and cardiovascular mortality in Moscow: new evidence of a causal association. J Epidemiol Community Health 1998;52:772-4.
257. Chenet L, Britton A, Kalediene R, et al. Daily variations in deaths in Lithuania: the possible contribution of binge drinking. Int J Epidemiol 2001;30:743-8.
258. Shkolnikov VM, McKee M, Chervyakov VV, et al. Is the link between alcohol and cardiovascular death among young Russian men attributable to misclassification of acute alcohol intoxication? Evidence from the city of Izhevsk. J Epidemiol Community Health 2002;56:171-4.
259. Wannamethee G, Shaper AG, Macfarlane PW, et al. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1995;91:1749-56.
260. Sexton PT, Walsh J, Jamrozik K, et al. Risk factors for sudden unexpected cardiac death in Tasmanian men. Aust N Z J Med 1997;27:45-50.
261. Jouven X, Desnos M, Guerot C, et al. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999;99:1978-83.
262. Escobedo LG, Caspersen CJ. Risk factors for sudden coronary death in the United States. Epidemiology 1997;8:175-80.
263. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 1985;5:141B-9B.
264. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
265. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
266. Jouven X, Charles MA, Desnos M, et al. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 2001;104:756-61.
267. Fuller CM, McNulty CM, Spring DA, et al. Prospective screening of 5,615 high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc 1997;29:1131-8.
268. Fuller CM. Cost effectiveness analysis of screening of high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc 2000;32:887-90.
269. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 1998;7:547-57.
270. Widerhorn J, Widerhorn AL, Rahimtoola SH, et al. WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. Am Heart J 1992;123:796-8.
271. Tawam M, Levine J, Mendelson M, et al. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 1993;72:838-40.
272. Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 1995;76:675-8.
273. Brodsky M, Doria R, Allen B, et al. New-onset ventricular tachycardia during pregnancy. Am Heart J 1992;123:933-41.
274. Gowda RM, Khan IA, Mehta NJ, et al. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. Int J Cardiol 2003;88:129-33.
275. Aronow WS. Treatment of ventricular arrhythmias in older adults. J Am Geriatr Soc 1995;43:688-95.
276. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349:675-82.
277. Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population: detection by 24-hour ambulatory electrocardiography. Chest 1982;81:302-7.
278. Lee KL, Tai YT. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety. Clin Cardiol 1997;20:372-7.
279. Aronow WS, Ahn C, Mercando AD, et al. Prevalence and association of ventricular tachycardia and complex ventricular arrhythmias with new coronary events in older men and women with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci 2002;57:M178-M180.
280. Volpi A, Cavalli A, Turato R, et al. Incidence and short-term prognosis of late sustained ventricular tachycardia after myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-3) Data Base. Am Heart J 2001;142:87-92.
281. Kannel WB, Cupples LA, D'Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J 1987;113:799-804.
282. Kuller L, Lilienfeld A, Fisher R. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease. Circulation 1966;34:1056-68.
283. Geelen P, Lorga FA, Primo J, et al. Experience with implantable cardioverter defibrillator therapy in elderly patients. Eur Heart J 1997;18:1339-42.
284. Panotopoulos PT, Axtell K, Anderson AJ, et al. Efficacy of the implantable cardioverter-defibrillator in the elderly. J Am Coll Cardiol 1997;29:556-60.
285. Saksena S, Mathew P, Giorgberidze I, et al. Implantable defibrillator therapy for the elderly. Am J Geriatr Cardiol 1998;7:11-3.
286. Silka MJ, Kron J, Dunnigan A, et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation 1993;87:800-7.
287. Sellers TD Jr., Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 1977;56:260-7.
288. Garson A Jr, Gillette PC, Titus JL, et al. Surgical treatment of ventricular tachycardia in infants. N Engl J Med 1984;310:1443-5.
289. Davis AM, Gow RM, McCrindle BW, et al. Clinical spectrum, therapeutic management, and follow-up of ventricular tachycardia in infants and young children. Am Heart J 1996;131:186-91.
290. Pfammatter JP, Paul T. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical profile and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. J Am Coll Cardiol 1999;33:2067-72.
291. Roden DM, Anderson ME. Proarrhythmia. In Kass RS, Clancey CE, editors. Handbook of Experimental Pharmacology: vol. 171. Basis and Treatment of Cardiac Arrhythmias. Boston, MA: Springer Verlag, 2006:288-304.
292. Antman EM, Wenger TL, Butler VP Jr., et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990;81:1744-52.
293. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002;297:1333-6.
294. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002;105:1943-8.
295. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988;77:392-7.
296. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
297. Bajaj AK, Woosley RL, Roden DM. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation 1989;80:994-1002.
298. Chouty F, Funck-Brentano C, Landau JM, et al. [Efficacy of high doses of molar lactate by the venous route in flecainide poisoning]. Presse Med 1987;16:808-10.
299. Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation 1989;80:1571-9.
300. Tada H, Sticherling C, Oral H, et al. Brugada syndrome mimicked by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol 2001;12:275.
301. Hoffman JR, Votey SR, Bayer M, et al. Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. Am J Emerg Med 1993;11:336-41.
302. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
303. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6 to 19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995;24:352-61.
304. Ferrari E, Benhamou M, Baudouy M. [Cardiotoxicity associated with trastuzumab (herceptin). An undesired effect leads towards a model of cardiac insufficiency]. Arch Mal Coeur Vaiss 2004;97:333-7.
305. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004;13:173-83.
306. Pichon MF, Cvitkovic F, Hacene K, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 2005;19:567-76.
307. Bu'Lock FA, Mott MG, Oakhill A, et al. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child 1996;75:416-22.
308. Li CK, Sung RY, Kwok KL, et al. A longitudinal study of cardiac function in children with cancer over 40 months. Pediatr Hematol Oncol 2000;17:77-83.
309. De WD, Suys B, Maurus R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res 1996;39:504-12.
310. Klewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 1992;19:394-401.
311. Lenk MK, Zeybek C, Okutan V, et al. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography. Turk J Pediatr 1998;40:373-83.
312. Johnson GL, Moffett CB, Geil JD, et al. Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring. J Pediatr Hematol Oncol 1996;18:72-5.
313. Postma A, Elzenga NJ, Haaksma J, et al. Cardiac status in bone tumor survivors up to nearly 19 years after treatment with doxorubicin: a longitudinal study 1. Med Pediatr Oncol 2002;39:86-92.
314. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy.Cancer 1993;71:493-509.